Essure-Attributed Symptoms: Follow-up of a Large Cohort after Device Removal: A Retrospective Nested Case-Control Study by Castelo-Branco Flores, Camil et al.
Citation: Castelo-Branco C, Duro-Gomez J, Romero-Dominguez M, Rodriguez-Marin AB, Povedano-Canizares B, et al. (2019) Essure-
Attributed Symptoms: Follow-up of a Large Cohort after Device Removal: A Retrospective Nested Case-Control Study. J Obstet Gyne-
col Probl: JOGP-100002.
Journal of Obstetrics 
and Gynecological Problems
Research Article Castelo-Branco C, et al. J Obstet Gynecol Probl: JOGP-100002.
Essure-Attributed Symptoms: Follow-up of a Large Cohort after 
Device Removal: A Retrospective Nested Case-Control Study
Camil Castelo-Branco1*, Jorge Duro-Gómez2, Marina Romero-Domínguez2, Ana Belén Rodríguez-Marín3,  Balbino Povedano-
Cañizares2 and Iuliia Naumova1 
1Institute Clinic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clinic-Institut 
d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona, Spain
2Department of Gynecology and Obstetrics, Reina Sofía University Hospital, Cordoba, Spain
3Department of Gynecology and Obstetrics, HospitalSan Juan de Dios, Córdoba, Spain
*Corresponding author: Camil Castelo-Branco, Institute Clinic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-
University of Barcelona, Hospital Clinic-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona, Spain. Tel: 
+34932275436, Fax: +3993227932; Email: castelobranco@ub.edu
Citation: Castelo-Branco C, Duro-Gomez J, Romero-Dominguez M, Rodriguez-Marin AB, Povedano-Canizares B, et al. (2019) Es-
sure-Attributed Symptoms: Follow-up of a Large Cohort after Device Removal: A Retrospective Nested Case-Control Study. J Obstet 
Gynecol Probl: JOGP-100002.
Received Date:  07 March, 2019; Accepted Date:  22 March, 2019; Published Date:  01 April, 2019
Volume 2019; Issue 011
Abstract
Objective: To analyse the reasons for Essure® removal in a large cohort of patients. 
Design: Retrospective 15-year study.
Setting: Office hysteroscopy unit in a teaching hospital.
Methods: From 2003 to 2015, 8024 Essure® device insertions were performed in a single centre in Córdoba (Spain). Of these, 156 
patients (1.89%) presented adverse events requiring device withdrawal (SG) A subset of 156 women matched for age, clinical char-
acteristics and time since insertion were used for case-control comparisons (CG). In 47 cases, the device had already been surgically 
removed. Three months later, patients were questioned regarding symptoms and their general condition.
Main Outcome Measure(s): Pre and post-operative adverse events, early postoperative and late complications (after the initial 3 
months) and patients’ satisfaction after procedures.
Results: In the SG, 23.08% (36) of the patients were allergic to nickel compared to only 1.28% (2) in the CG (p<0.01). No differences 
were found in insertion difficulty or pain or related to the time with the device. Surprisingly, satisfaction was higher at 3 months in the 
SG compared to the CG (100% vs. 90.90 %, respectively (p=0.01)). Currently, 58.61% (93) of the SG and 1.28 % (2) of the CG report 
pelvic pain as the most bother some symptom (p<0.01). The SG described abundant menstrual bleeding, allergy, asthenia, polyarthral-
gia and urinary tract infection. Of the 47 patients who had already undergone surgical device removal, 78.72% (37) reporting feeling 
well/very well, and 85.10% (40) felt better than before surgery. However, up to 93.67% (43) still had some complaints. 
Conclusion: Appropriate patient selection and careful preoperative assessment are required. Women should be informed about the 
benefits and risks of hysteroscopy and traditional sterilisation.
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Tweetable Abstract
Following Essure® insertion some women present symptoms, 
including pain, leading to device removal.
Introduction
The Essure® device (Bayer HealthCare Pharmaceuticals, 
Leverkusen, Germany) was approved by the US Food and Drug 
Administration (FDA) as a method of female sterilisation in 2002. 
The device is introduced into the isthmus of the uterine tube by 
ambulatory hysteroscopy [1]. Imaging tests are usually performed 
after 12 weeks to assess the location of the device. In general, after 
insertion, the users are very satisfied with the procedure, being 
highly effective and with a pregnancy rate of 0.15% [2-4].
Since 2013 some patients have referred different symptoms 
that appear after the insertion of the device and a small percentage 
of them subsequently choose to have the Essure® inserts removed 
due to regret or perceived side effects. Complications and 
complaints associated with the micro inserts include inadequate 
placement, unplanned pregnancy, infection, and chronic pelvic 
pain. However, most of the data is from case-reports or from 
short series and, in addition, there is scant evidence related to the 
improvement in the symptoms after surgical removal of the Essure 
inserts. In 2016, the FDA issued a warning recommending the need 
for post-marketing studies in which gynaecologists identify and 
record the adverse events referred by their patients [5]. Following 
this recommendation, we designed the present study with the aim 
of analysing the causes leading to surgical removal of the Essure® 
device in a large cohort of patients.
Methods
Patients: From 2003 to 2015, 8024 Essure® device insertions 
were carried out in a single centre (Hospital Reina Sofía, Cordoba, 
Spain). The insertion and follow-up procedures have been described 
elsewhere [1,2]. Three months after device insertion, a survey 
was conducted to detect possible adverse events and to know 
the degree of patient satisfaction with the device [3]. Among this 
sample, from December 2015 to May 2017, 156 (1.89%) patients 
presented one or more adverse event (AE) probably related to the 
Essure® device and requested its removal. In 47 cases the Essure® 
device had already been removed. Additionally, a subset of 156 
women taken from the entire sample and matched for age, time 
of insertion and clinical characteristics were used for case-control 
comparisons.
Essure Micro-insert: The Essure micro-insert is a spring-like 
device that consists of a stainless-steel inner coil, a nickel titanium 
expanding outer coil, and polyethelene terephthalate (PET) fibers. 
The PET fibers are wound in and around the inner coil. The micro-
insert is 4 cm in length and 0.8 mm in diameter in its wound down 
configuration. When released from the delivery system, the outer 
coil expands to 1.5 to 2.0 mm in diameter to anchor the micro-
insert in the varied diameters and shapes of the fallopian tube. The 
spring- like device is intended to provide the necessary anchoring 
forces during the acute phase of device implantation during which 
time the PET fibers stimulate tissue in-growth into the coils of the 
Essure® micro-insert and around the PET fibers.
Protocol: A comprehensive clinical history was obtained including 
personal background, allergies, symptoms and the reason why 
they considered the symptoms to be related to the device. Women 
requesting device removal underwent laparoscopic bilateral 
salpingectomy. Three months after device removal, a structured 
interview was conducted with the aim of knowing the symptoms 
and feelings after device withdrawal.
Adverse Event Monitoring: An adverse event was defined 
as any unfavourable or unintended sign or symptom presented 
or reported by the subject regardless of its relationship with the 
device. Each patient was carefully monitored for adverse events, 
including alterations in clinical and laboratory tests considered to be 
clinically relevant by the investigator. The investigator questioned 
the patient about the presentation of adverse events and recorded 
those reported. All the adverse events with inconsistencies in 
terms of date correlation with Essure® insertion were considered 
as possibly unrelated to the device. Additionally, adverse events in 
patients receiving other treatments simultaneously were assumed 
to not be clearly related to only Essure®. The possible causality 
was determined by the investigator reviewing the clinical data of 
each patient.
Statistical analysis: Results were expressed as means ± 
standard-deviation for quantitative variables and as total numbers 
and percentages for qualitative variables. The data were analysed 
using a personal computer based software package (G-Stat 2.0. 
Glaxo Smith Kline, Tres Cantos. Madrid). Normal distribution 
and variance homogeneity were verified by the Shapiro-Wilk test, 
and Levene and Bartlett tests. The Student’s t test was used to 
compare the mean scores between groups. Intergroup differences 
were evaluated with ANOVA or Kruskall-Wallis according to 
homogeneity of variance measured with the Bartlet’s test. The Chi 
squared test was used for the interpretation of qualitative variables. 
The level of significance was established at 5% (p<0.05).
Results
The clinical characteristics of the patients studied are shown 
in (Table 1). Thirty-six patients (23.08%) in the study group (SG) 
were allergic to nickel compared to only 4.49% (n=7) in the 
control group (CG) (p<0.01). No differences were found in other 
metal allergies, years since device insertion, previous joint pain, 
mental disorder, fibromyalgia, previous interventions or previous 
deliveries.
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Age (years) 36.74 ± 0.41 36.38 ± 0.44 0.56
Years since device insertion 5.78 ± 0.25 5.75 ± 0.27 0.94
Nickel allergy 36 (23.08) 7(4.49) <0.01
Other metal allergy 23 (14.74) 16(10.26) 0.23
Previous joint pain 8 (5.13) 7 (4.49) 0.79
Mental disorder 7 (4.52) 11 (7.05) 0.33
Fibromyalgia 3 (1.93) 2(98.72) 0.65
Previous surgery 0.33 ± 0.04 0.33 ± 0.04 0.30
Previous deliveries 2.21 ± 0.07 2.40 ± 0.08 0.08
Insertion without difficulty 110 (70.51) 119 (76.28) 0.20
Significant pain during insertion 13 (8.33) 13 (8.33)
Asymptomatic patients after 3 months 125 (80.12) 122 (78.21) 0.70
Days with pain after insertion 1.84 ± 0.06 1.78 ± 0.07 0.54
Patients score (1-10) 9.55 ± 0.06 9.48 ± 0.06 0.47
Satisfied or very satisfied patients 153 (98.08) 150 (96.15) 0.31
Table 1: Clinical characteristics of the patients studied. Data are given as mean ± standard deviation for quantitative values and as total numbers and 
percentages for qualitative values. (SG: study group; CG: control group).
No differences were detected between groups regarding the 
ease of insertion and pain during the procedure. The 156 users 
in the SG had had the device for a mean of 5.78 ± 0.25 years 
compared to 5.75 ± 0.27 in the CG (p=0.94). On comparing the 
difficulty in insertion between cases and controls, in 110 (70.51%) 
and 119 (76.28%) women, respectively, the insertion was carried 
out without problems (p=0.50). On the other hand, up to 8.33% 
(13) of women in both groups referred significant pain during 
insertion.
Three months after device insertion 80.12% (125) of 
the patients in the SG were asymptomatic while the remaining 
patients 19.88% (31) reported mild or moderate pain at only 1.84 
± 0.06 days after insertion. On the other hand, 78.21% (122) of 
the patients in the CG were asymptomatic (p=0.70) while the 
remaining patients reported pain for1.78 ± 0.07days (p=0.54). At 
this time, no differences were observed in patient satisfaction or 
related adverse events.
Currently, 58.61% (93) of the patients in the SG and 2.56 % 
(4) in the CG describe pelvic pain as being the most bothersome 
symptom (p<0.01). A total of 17 women (10.89%) in the SG reported 
abnormal uterine bleeding in the form of abundant menstrual 
haemorrhage compared to 4.49% (7) in the CG (p=0.03). Allergy 
was reported in 5.12% (8) of SG patients versus 0 (0) in the CG 
(p=0.02). In addition, more women in the SG had polyarthralgia 
and urinary tract infection (4.48% vs. 0%, respectively (p=0.03)). 
Moreover, some patients in the SG described additional complaints 
(Table 2) (Figure 1) at 15.59 ± 1.87 months after device insertion 
compared to 9.20 ± 5.50 months in the CG. Pain treatment included 
the use of NSAIDs or metamizole in 58.33% (91) and 2.56% 
(4) of cases in the SG and the CG respectively, and hormonal 
contraceptives or antifibrinolytics were prescribed to decrease 
bleeding in 3.2% (5) of women in the SG, whereas no treatment 
was required in the CG.
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Figure 1: Symptoms reported by patients requesting Essure® removal (N=156).





Pelvic pain 93 (58.61) 4 (2.56) <0.01
Headache 5 (3.2) 3(1.92)              0.43
Asthenia 6 (3.84) 1(0.64) 0.09
Lower back pain 5 (3.21) 4(2.56) 0.73
Allergy 
 8 (5.12) 0(0) 0.01
Gastrointestinal symptoms 2(1.28) 1(0.64) 0.56
Dyspareunia 1(0.64) 1(0.64)
Abundant menstrual haemorrhage 17 (10.89) 7 (4.49) 0.03
Cramps 2 (1.28) 0(0) 0.27
Polyarthralgia 7 (4.48) 0(0) 0.03
Urinary tract infection 7 (4.48) 0(0) 0.03
Others 
 3 (1.92) 1(0.64) 0.31
Table 2: The most bothersome symptoms reported by the patients included in the study. Data are given as total numbers and as percentages in brackets. 
*SG: study group; CG: control group.
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Among the reasons for device withdrawal, the immediacy 
of Essure® insertion and symptom debut was reported by 48.07% 
(75) of the women. Up to 10.25% (16) of the patients explained 
that they had not previously experienced the present complaints, 
and 13.46% (21) reported that the reporting of possible adverse 
events appearing in journals and on social media led to their 
claim. Likewise, 8.97% (14) requested device removal after being 
recommended to do so by another doctor. 
In the SG, 47 patients underwent further surgery. In 97.88% 
(46) of the cases device removal was by laparoscopy and in one 
case by hysteroscopy. Complications included 4 hysterectomies 
due to incomplete extraction of the device (8.51%). In 1 patient, a 
cornual incision was needed to remove the device. Three months 
later, 78.72% (37) of the patients reported feeling well or very well, 
and 85.10% (40) reported feeling better than before the surgery 
(Figure 2). This improvement occurred within the first month after 
surgery in 87.23% (41) of cases. However, up to 93.67% (43) of 
the patients continued to describe some complaints (headaches, 
pain, alopecia) following device removal.
How patients feel after removal of the device (n=47) (%)
Figure 2: Degree of patient satisfaction after Essure® removal (N=47).
No relevant changes were observed in the uterus at the 
time of laparoscopy; however, up to 25.53% (12) of patients had 
peritoneal adhesions, 6.38% (3) endometriosis and in 1 patient 
bilateral hydrosalpinx was found. Histological examination of the 
uterine tube following removal of the device showed fibrosis and 
minimal and non-specific changes in 12.76% (6), 38.39% (18), 
and 38.39% (18) of the cases, respectively and 10.63% (5) showed 
a normal tubal histology.
Discussion
Several studies have reported that patients carrying the 
Essure are highly satisfied with the device [3,6]. As in the study 
by Chudnoff, we found that the most common symptoms are 
pelvic pain, irregular menstruation, dyspareunia and spotting [7]. 
However, while in the study by Chudnoff the patients reported 
the appearance of symptoms along the 5-year follow-up period, 
in the present study, the debut of symptoms varied greatly, with 
some patients describing symptoms immediately after device 
insertion and others reporting problems at 12 years. In addition, in 
the survey performed at three months, no symptoms were referred 
immediately after insertion [3], although at present some patients 
have reported that they had actually had the symptoms since the 
day after device insertion. These reports merit special attention 
since it is well known that some asymptomatic patients may start 
to perceive adverse events after having heard about them from 
other patients or on the media or social networks [8].  
Pelvic pain is the main symptom described by most patients. 
In the study by Yunker, 7.1% of patients reported pain 3 months 
after device insertion which continued 6 months later in 4.2% 
of the cases [9]. Franchini et al. described minimal pain after 
insertion in 1968 women, with only 9 cases of intractable pelvic 
pain [10].  In contrast, in our sample, 19.88% of the women in 
the SG only referred mild or moderate pain for 1.84 ± .06 days 
after insertion. Moreover, Perkins et al. suggested that these pain 
rates were lower than in patients who opted fortubal ligation [11]. 
Likewise, in our study, pain prior to insertion and a history of 
fibromyalgia were found to be the most valuable predictors for 
long-term pain complaints [9]. In addition, in the present series, 
a significant number of patients in the SG group presented some 
type of mental illness. Therefore, in order to determine whether 
symptoms may be attributable to Essure®, it a necessary to obtain a 
comprehensive medical history to establish an adequate diagnosis 
and exclude other potential causes. On the other hand, a study by 
Perkins demonstrated that pain rates after Essure insertion were 
lower compared with those observed after laparoscopic tubal 
ligation [11].
Device removal in symptomatic patients usually correlates 
with an improvement in symptoms. In a recent study done by 
Britoin a short series of 11 patients, up to 72% of women reported 
an improvement after resection, while the rest remained the same 
[12]. In contrast, in the present series, 85.10% of the patients 
described an improvement suggesting that a large proportion of 
symptoms may not be due to the device.
A large number of patients receiving the Essure device are 
allergic to nickel. Previous studies have reported a low incidence 
of allergic patients with a risk of sensitisation after device insertion 
[13,14]. However, in the present study, 23.08% of the subjects in 
the SG were allergic to nickel versus 7.05% in the CG (p<0.01), 
and 14.74% and 10.26, respectively were allergic to other metals, 
suggesting that patients allergic to other metals may also have 
a nickel allergy. Therefore, nickel and metal allergies must be 
considered when indicating Essure® as a method of sterilisation.
Although the device can be successfully removed by 
hysteroscopy, the manufacturer rules out this procedure [15,16]. 
Therefore, in the absence of contraindication, laparoscopy is the 
preferred technique since salpingectomy conserves sterilisation 
and provides prophylax is against epithelial ovarian carcinoma 
[17,18].
Regarding the possibility of surgical intervention and 
hysterectomies, Jokinen et al. described a higher frequency of 
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these procedures when the Fisher sterilisation technique was 
performed [19]. In our series, of the 47 surgical procedures carried 
out for device removal, 4 (8.51%) involved hysterectomies due 
to the inability to remove all the components of the device by 
salpingectomy. Patients should therefore be informed about the 
possibility of a subsequent hysterectomy for complete removal of 
the device.
Some studies have reported alterations in menstrual pattern 
following Essure® insertion. Bradley described that 5 years after 
insertion the most common complaints were irregular menstruation 
(14.8%), intermonth bleeding (18.8%), heavy menstrual flow 
(37.5%) and low menstrual flow (23.3%) [6]. Perkins highlighted 
the greater rate of abnormal uterine bleeding with hysteroscopy 
sterilisation compared to laparoscopic procedures (26.8% versus 
22.3%) [10]. In the present series, most of alterations in the bleeding 
pattern improved after device withdrawal, although abnormal 
bleeding continued to be reported by 23.72% of the cases.
This study is mainly limited by its retrospective cohort 
case-control design and by the lack of more objective measures 
such Bold-fMRI, C-polymodal nociceptors activation or micro 
neurographic records. The survey did not ask the participants if 
they had been previously diagnosed with fibromyalgia or if they 
had presented pelvic pain preceding insertion of the device, all 
these data was recorded after the patient complained with pain. 
Other limitations include the lack of data on pathologies that may 
course with neuropathic pain such as diabetes or postherpetic 
neuralgia. Moreover, in the present study, the condition of patients 
carrying Essure® was assessed, showing a wide range of symptoms 
which partially improved upon device withdrawal being difficult 
to demonstrate a cause-effect relationship. Further well-designed 
studies, able to establish a potential causal relationship between 
Essure® and the above-mentioned symptoms are needed. 
According to Advancing Minimally Invasive Gynecology 
Worldwide (AAGL) [20], appropriate patient selection and 
careful preoperative assessment are required when considering 
the use of any intrauterine device. Moreover, women should be 
informed about the benefits and potential risks of hysteroscopy 
and traditional sterilisation procedures [21]. 
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